On April 16, 2026, OpenAI announced the launch of GPT-Rosalind, which is available as a research preview to eligible customers in ChatGPT, Codex, and API. The model is specifically designed for biology, drug development, and translational medicine research, aiming to address challenges posed by massive datasets and specialized terminology barriers.
